Acronym
(OSDI)
Description
The OSDI, which was created by the Outcomes Research Group at Allergan Inc in order to quickly assess the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision.
This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient’s life.[6] The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to “none of the time” and 4 corresponding to “all of the time.” A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.
The OSDI assesses quality of life measures, which aligns the questionnaire with Federal Food and Drug Administration’s emphasis on utilizing patient-reported outcomes in order to support medicinal product submissions and clinical drug trial efficacy. Tear break up time is another way that clinicians assess dry eye disease. When OSDI and tear break up time were analyzed, a statistically significant inverse correlation between the test scores was found; the higher or worse the OSDI score, the lower or worse the tear break up time was
Area of assessment
Function/disability/performance,
Quality of life,
Vision.
Condition
Eye/vision.
Age Group
Other
Literature on Arabic translation/validation of measure
| Author/link to article |
Publication year |
Population |
Sample Size |
Access to measure |
| Age |
Gender |
Condition |
Country |
|
Bakkar, M
|
2021
|
31.21±13.2 |
Both |
General population
|
Jordan
|
200
|
Pay |
